The Effects and Mechanisms of Mindfulness Based Cognitive Therapy (MBCT) on Depressive Symptoms and Depression Relapse
NCT ID: NCT01145872
Last Updated: 2014-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
92 participants
INTERVENTIONAL
2010-07-31
2013-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mindfulness Based Cognitive Therapy
Mindfulness Based Cognitive Therapy
Health Enhancement Program
Health Enhancement Program
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mindfulness Based Cognitive Therapy
Health Enhancement Program
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* be 18-55 years of age
* meet enhanced DSM-IV criteria for remission of MDD, recurrent and have a history of three or more previous episodes of DSM-IV major depression in the absence of a history of mania or hypomania
* at least one of those episodes was within the past two years
* participant must be in remission and if on antidepressant medication (ADM), they must be on a stable dose with no change in type or amount for past 12 weeks or participants must be off ADM at T1 for at least the preceding 12 weeks
* have, at screening assessment, residual depressive symptoms indicated by a Beck Depression Inventory-II (BDI-II;\[72\]) score between 6-19.
Exclusion Criteria
* schizophrenia or borderline personality disorder
* current suicidal thoughts and/or suicide attempt in last two months
* current anxiety disorder if it constitutes the predominant aspect of the clinical presentation and requires primary treatment not offered in the project
* substance abuse or dependence within last three months
* dementia or subnormal intellectual potential
* current obsessive-compulsive disorder
* current eating disorder
* history of previous mindfulness training or more than eight lifetime sessions of CBT
* current use of psychotherapy or counseling
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stanford University
OTHER
University of Colorado, Boulder
OTHER
University of Denver
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amanda Shallcross
Post-Doctoral Researcher
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Denver
Denver, Colorado, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.